O	0	4	Role	Role	NN	B-NP
O	5	7	of	of	IN	B-PP
O	8	19	interleukin	interleukin	NN	B-NP
O	20	21	1	1	CD	I-NP
O	22	24	in	in	IN	B-PP
O	25	32	antigen	antigen	NN	B-NP
O	32	33	-	-	HYPH	B-NP
O	33	41	specific	specific	JJ	I-NP
B-Cell	42	43	T	T	NN	I-NP
I-Cell	44	48	cell	cell	NN	I-NP
O	49	62	proliferation	proliferation	NN	I-NP
O	62	63	.	.	.	O

O	64	67	The	The	DT	B-NP
O	68	72	role	role	NN	I-NP
O	73	75	of	of	IN	B-PP
O	76	87	interleukin	interleukin	NN	B-NP
O	88	89	1	1	CD	I-NP
O	90	91	(	(	(	O
O	91	93	IL	IL	NN	B-NP
O	94	95	1	1	CD	I-NP
O	95	96	)	)	)	O
O	97	99	in	in	IN	B-PP
O	100	105	human	human	JJ	B-NP
O	106	113	antigen	antigen	NN	I-NP
O	113	114	-	-	HYPH	B-NP
O	114	122	specific	specific	JJ	I-NP
B-Cell	123	124	T	T	NN	I-NP
I-Cell	125	129	cell	cell	NN	I-NP
O	130	143	proliferation	proliferation	NN	I-NP
O	144	147	was	be	VBD	B-VP
O	148	156	examined	examine	VBN	I-VP
O	156	157	.	.	.	O

O	158	163	Nylon	Nylon	NN	B-NP
O	164	168	wool	wool	NN	I-NP
O	168	169	-	-	HYPH	B-NP
O	169	177	purified	purify	VBN	I-NP
B-Cell	178	179	T	T	NN	I-NP
I-Cell	180	185	cells	cell	NNS	I-NP
O	186	198	proliferated	proliferate	VBN	B-VP
O	199	201	in	in	IN	B-PP
O	202	205	the	the	DT	B-NP
O	206	214	presence	presence	NN	I-NP
O	215	217	of	of	IN	B-PP
B-Cell	218	228	autologous	autologous	JJ	B-NP
I-Cell	229	238	monocytes	monocyte	NNS	I-NP
O	239	240	(	(	(	O
B-Cell	240	242	Mo	Mo	NNP	B-NP
O	242	243	.	.	.	O
O	243	244	)	)	)	O
O	245	251	pulsed	pulse	VBD	B-VP
O	252	255	for	for	IN	B-PP
O	256	258	18	18	CD	B-NP
O	259	260	h	h	NN	I-NP
O	261	265	with	with	IN	B-PP
O	266	273	tetanus	tetanus	NN	B-NP
O	274	280	toxoid	toxoid	NN	I-NP
O	281	282	(	(	(	O
O	282	284	TT	TT	NN	B-NP
O	284	285	)	)	)	O
O	286	293	antigen	antigen	NN	B-NP
O	294	295	(	(	(	O
B-Cell	295	297	Mo	Mo	NNP	B-NP
O	297	298	.	.	.	I-NP
O	298	300	TT	TT	NNP	I-NP
O	300	301	)	)	)	O
O	301	302	.	.	.	O

O	303	314	Irradiation	Irradiation	NN	B-NP
O	315	317	of	of	IN	B-PP
B-Cell	318	320	Mo	Mo	NN	B-NP
O	320	321	.	.	.	O
O	321	323	TT	TT	NN	B-NP
O	324	328	with	with	IN	B-PP
O	329	340	ultraviolet	ultraviolet	NN	B-NP
O	341	342	(	(	(	O
O	342	344	UV	UV	NN	B-NP
O	344	345	)	)	)	O
O	346	351	light	light	NN	B-NP
O	352	353	(	(	(	O
O	353	355	72	72	CD	B-NP
O	356	357	J	J	NN	I-NP
O	357	358	/	/	SYM	B-NP
O	358	360	m2	m2	NN	I-NP
O	360	361	)	)	)	O
O	362	371	abolished	abolish	VBD	B-VP
O	372	377	their	their	PRP$	B-NP
O	378	386	capacity	capacity	NN	I-NP
O	387	389	to	to	TO	B-VP
O	390	397	support	support	VB	I-VP
B-Cell	398	399	T	T	NN	B-NP
I-Cell	400	404	cell	cell	NN	I-NP
O	405	418	proliferation	proliferation	NN	I-NP
O	419	422	and	and	CC	O
O	423	434	drastically	drastically	RB	B-VP
O	435	442	reduced	reduce	VBD	I-VP
O	443	448	their	their	PRP$	B-NP
O	449	457	capacity	capacity	NN	I-NP
O	458	460	to	to	TO	B-VP
O	461	468	secrete	secrete	VB	I-VP
O	469	471	IL	IL	NN	B-NP
O	472	473	1	1	CD	I-NP
O	474	479	after	after	IN	B-PP
O	480	491	stimulation	stimulation	NN	B-NP
O	492	496	with	with	IN	B-PP
O	497	511	Staphylococcus	Staphylococcus	NN	B-NP
O	512	517	albus	albus	NN	I-NP
O	517	518	.	.	.	O

O	519	522	The	The	DT	B-NP
O	523	529	defect	defect	NN	I-NP
O	530	532	in	in	IN	B-PP
O	533	540	antigen	antigen	NN	B-NP
O	541	553	presentation	presentation	NN	I-NP
O	554	561	induced	induce	VBN	B-VP
O	562	564	by	by	IN	B-PP
O	565	567	UV	UV	NN	B-NP
O	568	579	irradiation	irradiation	NN	I-NP
O	580	582	of	of	IN	B-PP
B-Cell	583	585	Mo	Mo	NN	B-NP
O	585	586	.	.	.	O
O	586	588	TT	TT	NN	B-NP
O	589	592	was	be	VBD	B-VP
O	593	601	reversed	reverse	VBN	I-VP
O	602	604	in	in	IN	B-PP
O	605	606	a	a	DT	B-NP
O	607	611	dose	dose	NN	I-NP
O	611	612	-	-	HYPH	B-NP
O	612	621	dependent	dependent	JJ	I-NP
O	622	628	manner	manner	NN	I-NP
O	629	631	by	by	IN	B-PP
O	632	635	the	the	DT	B-NP
O	636	644	addition	addition	NN	I-NP
O	645	647	of	of	IN	B-PP
O	648	651	two	two	CD	B-NP
O	652	661	different	different	JJ	I-NP
O	662	674	preparations	preparation	NNS	I-NP
O	675	685	containing	contain	VBG	B-VP
O	686	691	human	human	JJ	B-NP
O	692	703	interleukin	interleukin	NN	I-NP
O	704	705	1	1	CD	I-NP
O	706	707	(	(	(	O
O	707	709	IL	IL	NN	B-NP
O	710	711	1	1	CD	I-NP
O	711	712	)	)	)	O
O	712	713	.	.	.	O

O	714	717	The	The	DT	B-NP
O	718	723	first	first	JJ	I-NP
O	724	735	preparation	preparation	NN	I-NP
O	736	745	consisted	consist	VBD	B-VP
O	746	748	of	of	IN	B-PP
B-Organism_substance	749	761	supernatants	supernatant	NNS	B-NP
O	762	764	of	of	IN	B-PP
B-Cell	765	767	Mo	Mo	NN	B-NP
O	767	768	.	.	.	O
O	769	779	stimulated	stimulate	VBN	B-VP
O	780	784	with	with	IN	B-PP
O	785	788	Con	Con	NN	B-NP
O	789	790	A	A	NN	I-NP
O	791	794	for	for	IN	B-PP
O	795	797	18	18	CD	B-NP
O	798	800	hr	hr	NN	I-NP
O	801	804	and	and	CC	B-PP
O	805	807	in	in	IN	B-PP
O	808	813	which	which	WDT	B-NP
O	814	817	Con	Con	NN	B-NP
O	818	819	A	A	NN	I-NP
O	820	828	activity	activity	NN	I-NP
O	829	832	was	be	VBD	B-VP
O	833	840	blocked	block	VBN	I-VP
O	841	843	by	by	IN	B-PP
O	844	849	alpha	alpha	SYM	B-NP
O	849	850	-	-	HYPH	B-NP
O	850	851	D	D	NN	I-NP
O	851	852	-	-	HYPH	B-NP
O	852	858	methyl	methyl	NN	I-NP
O	858	859	-	-	HYPH	O
O	859	868	mannoside	mannoside	NN	B-NP
O	869	870	(	(	(	O
B-Cell	870	872	Mo	Mo	NN	B-NP
O	872	873	.	.	.	O
O	873	874	-	-	HYPH	B-NP
O	874	877	Con	Con	NN	I-NP
O	878	879	A	A	NN	I-NP
O	879	880	-	-	HYPH	O
O	880	883	Sup	Sup	NN	B-NP
O	883	884	)	)	)	O
O	884	885	.	.	.	O

O	886	889	The	The	DT	B-NP
O	890	896	second	second	JJ	I-NP
O	897	908	preparation	preparation	NN	I-NP
O	909	918	consisted	consist	VBD	B-VP
O	919	921	of	of	IN	B-PP
O	922	927	human	human	JJ	B-NP
O	928	930	IL	IL	NN	I-NP
O	931	932	1	1	CD	I-NP
O	933	942	partially	partially	RB	B-VP
O	943	951	purified	purify	VBN	I-VP
O	952	956	from	from	IN	B-PP
B-Organism_substance	957	969	supernatants	supernatant	NNS	B-NP
O	970	972	of	of	IN	B-PP
O	973	978	human	human	JJ	B-NP
B-Cell	979	989	peripheral	peripheral	JJ	I-NP
I-Cell	990	995	blood	blood	NN	I-NP
I-Cell	996	1007	mononuclear	mononuclear	JJ	I-NP
I-Cell	1008	1013	cells	cell	NNS	I-NP
O	1014	1024	stimulated	stimulate	VBN	B-VP
O	1025	1029	with	with	IN	B-PP
O	1030	1031	S	S	NN	B-NP
O	1031	1032	.	.	.	O
O	1033	1038	albus	albus	NN	B-NP
O	1038	1039	.	.	.	O

O	1040	1044	This	This	DT	B-NP
O	1045	1047	IL	IL	NN	I-NP
O	1048	1049	1	1	CD	I-NP
O	1050	1060	copurified	copurifie	VBN	B-VP
O	1061	1065	with	with	IN	B-PP
O	1066	1071	human	human	JJ	B-NP
B-Cell	1072	1081	leukocyte	leukocyte	NN	I-NP
O	1082	1089	pyrogen	pyrogen	NN	I-NP
O	1090	1091	(	(	(	O
O	1091	1093	LP	LP	NN	B-NP
O	1093	1094	)	)	)	O
O	1095	1098	and	and	CC	O
O	1099	1102	was	be	VBD	B-VP
O	1103	1109	termed	term	VBN	I-VP
O	1110	1112	IL	IL	NN	B-NP
O	1113	1114	1	1	CD	I-NP
O	1114	1115	/	/	SYM	I-NP
O	1115	1117	LP	LP	NN	I-NP
O	1117	1118	.	.	.	O

O	1119	1123	Both	Both	CC	O
O	1124	1126	IL	IL	NN	B-NP
O	1127	1128	1	1	CD	I-NP
O	1128	1129	-	-	HYPH	B-NP
O	1129	1139	containing	contain	VBG	I-NP
O	1140	1152	preparations	preparation	NNS	I-NP
O	1153	1161	enhanced	enhance	VBD	B-VP
O	1162	1165	the	the	DT	B-NP
O	1166	1174	response	response	NN	I-NP
O	1175	1177	of	of	IN	B-PP
O	1178	1183	C57BL	C57BL	NN	B-NP
O	1183	1184	/	/	SYM	O
O	1184	1185	6	6	CD	B-NP
O	1186	1191	mouse	mouse	NN	I-NP
B-Cell	1192	1202	thymocytes	thymocyte	NNS	I-NP
O	1203	1205	to	to	TO	B-PP
O	1206	1224	phytohemagglutinin	phytohemagglutinin	NN	B-NP
O	1224	1225	.	.	.	O

O	1226	1227	A	A	DT	B-NP
O	1228	1234	rabbit	rabbit	NN	I-NP
O	1235	1243	antibody	antibody	NN	I-NP
O	1244	1246	to	to	TO	B-PP
O	1247	1252	human	human	JJ	B-NP
O	1253	1255	IL	IL	NN	I-NP
O	1256	1257	1	1	CD	I-NP
O	1257	1258	/	/	SYM	I-NP
O	1258	1260	LP	LP	NN	I-NP
O	1261	1270	inhibited	inhibit	VBD	B-VP
O	1271	1274	the	the	DT	B-NP
O	1275	1283	capacity	capacity	NN	I-NP
O	1284	1286	of	of	IN	B-PP
B-Cell	1287	1288	T	T	NN	B-NP
I-Cell	1289	1294	cells	cell	NNS	I-NP
O	1295	1297	to	to	TO	B-VP
O	1298	1309	proliferate	proliferate	VB	I-VP
O	1310	1312	in	in	IN	B-PP
O	1313	1321	response	response	NN	B-NP
O	1322	1324	to	to	TO	B-PP
B-Cell	1325	1327	Mo	Mo	NN	B-NP
O	1327	1328	.	.	.	O
O	1328	1330	TT	TT	NN	B-NP
O	1331	1334	and	and	CC	O
O	1335	1344	inhibited	inhibit	VBD	B-VP
O	1345	1348	the	the	DT	B-NP
O	1349	1357	capacity	capacity	NN	I-NP
O	1358	1360	of	of	IN	B-PP
B-Cell	1361	1363	Mo	Mo	NN	B-NP
O	1363	1364	.	.	.	O
O	1364	1365	-	-	HYPH	B-NP
O	1365	1368	Con	Con	NN	I-NP
O	1369	1370	A	A	NN	I-NP
O	1370	1371	-	-	HYPH	O
O	1371	1374	Sup	Sup	NN	B-NP
O	1375	1377	to	to	TO	B-VP
O	1378	1390	reconstitute	reconstitute	VB	I-VP
O	1391	1394	the	the	DT	B-NP
B-Cell	1395	1396	T	T	NN	I-NP
I-Cell	1397	1401	cell	cell	NN	I-NP
O	1402	1410	response	response	NN	I-NP
O	1411	1413	to	to	TO	B-PP
O	1414	1416	UV	UV	NN	B-NP
O	1416	1417	-	-	HYPH	B-NP
O	1417	1427	irradiated	irradiated	JJ	I-NP
B-Cell	1428	1430	Mo	Mo	NNP	I-NP
O	1430	1431	.	.	.	I-NP
O	1431	1433	TT	TT	NNP	I-NP
O	1433	1434	.	.	.	O

O	1435	1437	IL	IL	NN	B-NP
O	1438	1439	1	1	CD	I-NP
O	1439	1440	/	/	SYM	I-NP
O	1440	1442	LP	LP	NN	I-NP
O	1443	1446	was	be	VBD	B-VP
O	1447	1450	not	not	RB	O
O	1451	1460	necessary	necessary	JJ	B-ADJP
O	1461	1464	for	for	IN	B-PP
B-Cell	1465	1466	T	T	NN	B-NP
I-Cell	1467	1472	cells	cell	NNS	I-NP
O	1473	1475	to	to	TO	B-VP
O	1476	1485	recognize	recognize	VB	I-VP
O	1486	1489	the	the	DT	B-NP
O	1490	1501	immunogenic	immunogenic	JJ	I-NP
O	1502	1508	moiety	moiety	NN	I-NP
O	1509	1518	presented	present	VBN	B-VP
O	1519	1521	by	by	IN	B-PP
B-Cell	1522	1524	Mo	Mo	NN	B-NP
O	1524	1525	.	.	NN	I-NP
O	1525	1526	,	,	,	O
O	1527	1534	because	because	IN	B-SBAR
B-Cell	1535	1545	monolayers	monolayer	NNS	B-NP
O	1546	1548	of	of	IN	B-PP
O	1549	1551	UV	UV	NN	B-NP
O	1551	1552	-	-	HYPH	B-NP
O	1552	1562	irradiated	irradiate	VBN	I-NP
B-Cell	1563	1565	Mo	Mo	NN	I-NP
O	1565	1566	.	.	.	I-NP
O	1566	1568	TT	TT	NN	I-NP
O	1569	1573	were	be	VBD	B-VP
O	1574	1584	equivalent	equivalent	JJ	B-ADJP
O	1585	1587	to	to	TO	B-PP
B-Cell	1588	1598	monolayers	monolayer	NNS	B-NP
O	1599	1601	of	of	IN	B-PP
O	1602	1614	unirradiated	unirradiated	JJ	B-NP
B-Cell	1615	1617	MO	MO	NN	I-NP
O	1617	1618	.	.	.	I-NP
O	1618	1620	TT	TT	NN	I-NP
O	1621	1623	in	in	IN	B-PP
O	1624	1629	their	their	PRP$	B-NP
O	1630	1638	capacity	capacity	NN	I-NP
O	1639	1641	to	to	TO	B-VP
O	1642	1648	adsorb	adsorb	VB	I-VP
O	1649	1651	TT	TT	NN	B-NP
O	1651	1652	-	-	HYPH	B-NP
O	1652	1660	reactive	reactive	JJ	I-NP
B-Cell	1661	1662	T	T	NN	I-NP
I-Cell	1663	1668	cells	cell	NNS	I-NP
O	1669	1681	specifically	specifically	RB	B-ADVP
O	1681	1682	.	.	.	O

O	1683	1694	Furthermore	Furthermore	RB	B-ADVP
O	1694	1695	,	,	,	O
O	1696	1699	the	the	DT	B-NP
O	1700	1708	addition	addition	NN	I-NP
O	1709	1711	of	of	IN	B-PP
O	1712	1718	rabbit	rabbit	NN	B-NP
O	1719	1727	antibody	antibody	NN	I-NP
O	1728	1730	to	to	TO	B-PP
O	1731	1733	IL	IL	NN	B-NP
O	1734	1735	1	1	CD	I-NP
O	1735	1736	/	/	SYM	I-NP
O	1736	1738	LP	LP	NN	I-NP
O	1739	1742	did	do	VBD	B-VP
O	1743	1746	not	not	RB	I-VP
O	1747	1756	interfere	interfere	VB	I-VP
O	1757	1761	with	with	IN	B-PP
O	1762	1765	the	the	DT	B-NP
O	1766	1774	capacity	capacity	NN	I-NP
O	1775	1777	of	of	IN	B-PP
O	1778	1780	UV	UV	NN	B-NP
O	1780	1781	-	-	HYPH	B-NP
O	1781	1791	irradiated	irradiate	VBN	I-NP
B-Cell	1792	1794	Mo	Mo	NN	I-NP
O	1794	1795	.	.	.	I-NP
O	1795	1797	TT	TT	NN	I-NP
O	1798	1800	to	to	TO	B-VP
O	1801	1807	adsorb	adsorb	VB	I-VP
O	1808	1810	TT	TT	NN	B-NP
O	1810	1811	-	-	HYPH	B-NP
O	1811	1819	reactive	reactive	JJ	I-NP
B-Cell	1820	1821	T	T	NN	I-NP
I-Cell	1822	1827	cells	cell	NNS	I-NP
O	1827	1828	.	.	.	O

O	1829	1832	The	The	DT	B-NP
O	1833	1840	results	result	NNS	I-NP
O	1841	1849	obtained	obtain	VBN	B-VP
O	1850	1852	in	in	IN	B-PP
O	1853	1857	this	this	DT	B-NP
O	1858	1863	study	study	NN	I-NP
O	1864	1872	indicate	indicate	VBP	B-VP
O	1873	1877	that	that	IN	B-SBAR
O	1878	1880	IL	IL	NN	B-NP
O	1881	1882	1	1	CD	I-NP
O	1883	1885	is	be	VBZ	B-VP
O	1886	1894	involved	involve	VBN	I-VP
O	1895	1897	in	in	IN	B-PP
O	1898	1905	optimal	optimal	JJ	B-NP
O	1906	1913	antigen	antigen	NN	I-NP
O	1913	1914	-	-	HYPH	B-VP
O	1914	1920	driven	drive	VBN	B-NP
O	1921	1934	proliferation	proliferation	NN	I-NP
O	1935	1937	of	of	IN	B-PP
O	1938	1943	human	human	JJ	B-NP
B-Cell	1944	1945	T	T	NN	I-NP
I-Cell	1946	1957	lymphocytes	lymphocyte	NNS	I-NP
O	1957	1958	.	.	.	O

